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Abstract
The hypocretins, also known as orexins, are two neuropeptides now commonly described as 
critical components to maintain and regulate the stability of arousal. Several lines of evidence 
have raised the hypothesis that hypocretin-producing neurons are part of the circuitries that 
mediate the hypothalamic response to acute stress. Intracerebral administration of hypocretin leads 
to a dose related reinstatement of drug and food seeking behaviors. Furthermore, stress-induced 
reinstatement can be blocked with hypocretin receptor 1 antagonism. These results, together with 
recent data showing that hypocretin is critically involved in cocaine sensitization through the 
recruitment of NMDA receptors in the ventral tegmental area, strongly suggest that activation of 
hypocretin neurons play a critical role in the development of the addiction process. The activity of 
hypocretin neurons may affect addictive behavior by contributing to brain sensitization or by 
modulating the brain reward system. Hypocretinergic cells, in coordination with brain stress 
systems may lead to a vulnerable state that facilitates the resumption of drug seeking behavior. 
Hence, the hypocretinergic system is a new drug target that may be used to prevent relapse of drug 
seeking.
The hypocretins (also known as orexins) are two neuropeptides, hypocretin-1 (hcrt-1) and 
hypocretin-2 (hcrt-2), derived from the same precursor gene (preprohypocretin) produced in 
a few thousand neurons localized in the perifornical area of the lateral hypothalamus. [1,2]. 
Hypocretin producing neurons project throughout the brain and especially to areas involved 
in energy homeostasis, arousal and brain reward. The distribution of hypocretin terminals is 
consistent with the partially overlapping but complementary distributions of the two 
hypocretin receptors [3,4]. Afferents to hypocretin neurons project from the basal forebrain, 
bed nucleus of the stria terminalis, lateral septum, preoptic area, and posterior hypothalamus 
[5].
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Evidence from multiple experiments indicate that hypocretin neurons in the lateral 
hypothalamus receive inputs from diverse sensory and limbic systems to provide a coherent 
output that results in the stability of the states of vigilance [6-8]
The hypocretins are critical for the maintenance of arousal
Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and 
cataplexy attacks. Narcoleptic patients also exhibit sleep onset REM direct transition from 
wakefulness to rapid-eye movement (REM) sleep [9], which are suggestive of the inability 
to control the boundaries between vigilance states. The link between hypocretins and 
narcolepsy was evidenced when positional cloning revealed that a mutation in the canine 
hypocretin receptor 2 segregated with a narcoleptic phenotype in dogs [10]. Furthermore, 
pre-prohypocretin knockout mice show periods of cataplexy-like attacks and sudden onset of 
REM sleep [11,12]. This narcolepsy-like phenotype is also observed in transgenic mice and 
rats with selective postnatal degeneration of hypocretin-expressing neurons [13,14] and in 
the narcolepsy condition can be rescued either by pharmacological or genetic means [15]. 
Also, human narcoleptic brains are practically devoid or hypocretin-producing neurons 
[16,17]. These data unequivocally demonstrate that narcolepsy is a disease of the 
hypocretinergic system.
Studies in transgenic animals have shown that, in addition to their key role in the regulation 
of transitions between vigilance states, the hypocretins may be involved in linking 
information about nutritional and metabolic state and promotion of arousal. Thus, while 
most mammals respond to reduced food availability by becoming more wakeful and active, 
transgenic mice depleted of hypocretin neurons fail to respond to fasting with increased 
activity and arousal [18]. Recent data also indicate that the hypocretinergic system receives 
input from the brain circuitry that modulates stress.
The hypocretinergic system may be a component of the stress response
Behavioral arousal is a key component of the stress response. A well-characterized 
physiological response to stress affects the hypothalamo-pituitary-adrenal (HPA) axis. Upon 
stress stimulus, synthesis of the corticotropin-releasing factor (CRF) is induced in the 
paraventricular nucleus of the hypothalamus. Stimulation of the pituitary corticotroph cells 
by CRF stimulates the production of the adrenocorticotropic hormone (ACTH). The primary 
target of ACTH is the adrenal gland from which ACTH stimulates the release of 
glucocorticoids, which in turn provide a feedback loop to the pituitary and hypothalamus to 
stop the response to stressful stimuli [19].
As discussed above, hypocretin-containing neurons are critical components of the circuitry 
that modulates and sets the arousal threshold [8]. Thus, one can expect a role for the 
hypocretinergic system in the “hyperarousal” state that characterizes stress. Indeed, icv 
injection of hcrt-1 increases food consumption [20-23], locomotor activity [24-26] and body 
temperature [27,28]. Moreover, central administration of hcrt-1 stimulates gastric acid 
secretion, increases arterial blood pressure, heart rate, cerebral blood flow and sympathetic 
nerve activity [29,30], and mice deficient in prepro hcrt display low sympathetic tone. [31].
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Increasing evidence suggests that hypocretin neurons receive afferents from neurons 
belonging to the brain stress system. CRF-containing terminals form synapses onto 
hypocretin neurons [32]. Intracellular recordings of hcrt neurons, identified by EGFP 
staining in hypothalamic slices from orexin/EGFP indicate that CRF directly depolarizes 
hypocretinergic cells [32]. This effect is likely mediated through CRFR1 since astressin, a 
CRF-R1 selective antagonist, blocked the CRF-induced depolarization of hypocretin 
neurons. The functional significance of the CRF-hypocretins interaction was tested during 
acute stress such as restraint or footshock stress. Restraint stress dramatically increases 
prepro-hypocretin mRNA steady state concentration [33]. Both acute stress paradigms 
induce c-Fos immunoreactivity in hypocretin-producing neurons of wild type mice. 
However, activation of c-Fos in hypocretinergic neurons after footshock and restraint stress 
was decreased in mice deficient in CRF-R1 [32]. These results suggest that the stress-
induced activation of hypocretinergic neurons occurs through the CRF-R1 receptor. The 
hypocretinergic system may be a component of the central response to acute stress activated 
by CRF (Figure 2).
Hypocretin neurons are reciprocally connected with NPY-containing neurons [34], another 
peptidergic system involved in the multiple responses to acute stress. [35]. Interestingly, icv 
administration of NPY increases sedation [36] and has anxiolytic activity in response to 
some stimuli [37-39]. NPY potently hyperpolarizes hypocretin neurons in vitro [40]. It is 
thus possible that some of the behavioral effects of NPY are mediated by inhibition of the 
hypocretinergic system.
This circuitry between CRF, hypocretin and NPY may have significant relevance in multiple 
physiological and pathological situations, and in particular in hyperaroused states associated 
with motivation and addiction.
The hypocretins and addiction
The relationship between stress and addiction is well established and the extended amygdala 
has been shown to play a key role in mediating both positive and negative reinforcement 
associated with drug addiction [41-43]. The extended amygdala is comprised of the medial 
subregion of the nucleus accumbens (shell of the nucleus accumbens), the bed nucleus of the 
stria terminalis, and the central nucleus of the amygdala. This structure receives numerous 
afferents from limbic regions, such as the basolateral amygdala and hippocampus, and sends 
not only afferents to the medial part of the ventral pallidum but also to the lateral 
hypothalamus, thus further defining the specific brain areas that interface classical limbic 
structures with the extrapyramidal motor system. Thus, the extended amygdala provides a 
connection for the basal forebrain to the classical reward systems of the lateral 
hypothalamus via the medial forebrain bundle reward system [44,45].
Interestingly, the hypocretinergic system projects to all the major components of the 
extended amygdala, namely, the central amygdala, the shell of the nucleus accumbens 
(NAcc) and the bed nucleus of the stria terminalis (BNST) (Figure 2) [4,46]. Since 
hypocretins have been shown to be involved in the GABAergic modulation of the 
mesolimbic dopamine system, [47-49], this peptidergic system fulfills all the 
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neuroanatomical and functional criteria to modulate critical connections that regulate both 
positive- and negative-reinforcing properties of drugs of abuse.
Several lines of evidence suggest that hypocretins are involved in the modulation of the 
brain reward function. First, both lesions experiments and the intracranial self-stimulation 
(ICSS) paradigm have suggested an important role of the lateral hypothalamus in reward 
[50,51]. Compared to other brain regions, ICSS in the LH, also called LHSS, is by far the 
most potent [52]. Secondly, maintenance of energy homeostasis requires the coordination of 
systems that regulate feeding, body temperature, autonomic and endocrine functions with 
those that modulate an appropriate state of arousal and motivation. The close interaction 
between the CRF and the hypocretin peptidergic systems [32,53-55], places hypocretin 
neurons as a key system in the integration of emotional stimuli.
To directly test whether the hypocretins were involved in the acquisition of drug 
consumption, we infused 0.2-1.5 nmoles of hcrt-1 into the brains of rats trained to self 
administer cocaine (0.25 mg/kg/infusion). No differences were observed compared with 
saline-treated rats after single or repeated injections of the peptide, at different periods of the 
circadian cycle, and at different exposure times to cocaine, using a fixed- or a progressive-
ratio schedule of reinforcement [56].
Thus, we concluded that hypocretin did not modulate cocaine intake in rats. However, we 
showed that intracerebroventricular (icv) infusions of hypocretin-1 led to a dose-related 
reinstatement of a previously extinguished cocaine seeking behavior. We have then 
demonstrated that the same dose of hcrt-1 elevated intracranial self-stimulation (ICSS) 
thresholds, indicating a decrease in excitability of brain reward systems. This effect was in 
sharp contrast to the well known cocaine-induced lowering of ICSS thresholds that is 
considered to reflect an increased sensitivity that underlies, or at least contributes to the 
positive affective state associated with drug consumption. In contrast, this long lasting 
reward deficit was similar to that observed after icv infusion of CRF [57] or after drug 
withdrawal [58,59]. These data provide strong evidence suggesting that hcrt-1 reinstated 
cocaine seeking by mechanisms different from increased dopamine release only [60]. 
Indeed, the blockade of hcrt-induced reinstatement of cocaine seeking by CRF/NA 
antagonism rather suggests that hypocretin and stress systems may closely interact to 
regulate cocaine seeking behavior. This hypothesis was later confirmed using a hcrt-1 
antagonist, SB 334867, to prevent footshock-induced reinstatement of a previously 
extinguished cocaine seeking behavior. Overall, these findings identify the hcrt system as a 
new mechanism by which stress could influence relapse to drug seeking and drug taking. 
Emerging evidence suggests long-lasting cocaine-induced neuroadaptations that give stress 
input access to mesolimbic circuitry and that predisposes stressed animals to relapse to 
cocaine seeking. CRF was shown to induce glutamate release in the VTA of cocaine-
experienced but not in cocaine naïve-rats [61]. Interestingly, hypocretins have been shown 
to act synergistically with glutamatergic afferents to depolarize both cholinergic neurons in 
the LDT [62] and dopaminergic neurons in the VTA [63] . Further, hypocretin has been 
shown to critically contribute to cocaine sensitization through the recruitment of NMDA 
receptors in the VTA [64]. Taken together, the result suggests that hypocretins, in 
coordination with CRF, could contribute to glutamate release facilitation which ultimately 
Boutrel and de Lecea Page 4













could lead to arousal/motivational systems activation, including both noradrenaline and 
dopamine systems. A chronic activation of such brain systems could lead to an allostatic 
state of brain reward system, or hedonic set point (see [65]), and could underlie vulnerability 
to relapse for drug seeking after a period of protracted abstinence and/or detoxification.
We propose that the Hcrt system (receiving sensory stimuli and relaying them to brainstem 
nuclei, the HPA axis and also to arousal- and stress-related forebrain regions) could be 
activated by chronic drug intoxication. At cessation of drug presentation, the hypocretin 
system may act as an alarm signal that would prepare the organism for withdrawal and its 
consequences on energy and fluid homoeostasis (such as starvation activates the hcrt to face 
its consequences on metabolic/caloric needs). In this context, leptin, which hyperpolarizes 
hypocretin neurons, also attenuates fasting-induced heroin-seeking behavior [66], and 
mutant mice deficient in Hcrt display diminished signs of precipitated opiate withdrawal 
[67]. The main question remains whether or not a chronically activated hypocretin system 
upon chronic drug exposure (and recurrent withdrawals) may elicit allostasis within the 
brain reward mechanisms as a means to maintain stability in the face of chronic demand, 
and ultimately lead to a particularly vulnerable state of the brain given that hypocretin 
priming by stress events may facilitate the resumption of drug seeking behavior even months 
or years after detoxification. Understanding the alterations in such fundamental homeostatic 
systems within the brain may be the key to prevent a variety of pathophysiological 
dysfunctions including affective and addictive disorders [68].
As a conclusion, we propose that the hypocretinergic system could play a relevant role in 
both homeostatic (upon stress stimuli as well as during drug withdrawal) and allostatic 
regulation of physiological functions related to arousal, stress and motivation (in the latter 
case, after a prolonged period of drug intoxication and/or during protracted abstinence). We 
therefore suggest that hypocretin may represent a target for preventing drug craving and 
vulnerability to relapse.
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